发明申请
US20130267599A1 USE OF TRANS-PALMITOLEATE IN IDENTIFYING AND TREATING METABOLIC DISEASE
有权
用于鉴别和治疗代谢性疾病的转基因药物的使用
- 专利标题： USE OF TRANS-PALMITOLEATE IN IDENTIFYING AND TREATING METABOLIC DISEASE
- 专利标题（中）： 用于鉴别和治疗代谢性疾病的转基因药物的使用
-
申请号： US13809181申请日： 2011-07-11
-
公开(公告)号： US20130267599A1公开(公告)日： 2013-10-10
- 发明人: Dariush Mozaffarian , Haiming Cao , Gokhan S. Hotamisligil
- 申请人： Dariush Mozaffarian , Haiming Cao , Gokhan S. Hotamisligil
- 申请人地址： US MA Cambridge
- 专利权人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE
- 当前专利权人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE
- 当前专利权人地址： US MA Cambridge
- 国际申请： PCT/US11/43517 WO 20110711
- 主分类号： C07C57/03
- IPC分类号： C07C57/03
摘要：
The present invention provides for a novel lipokine, trans-C16:1n7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, low concentrations of trans-C16:1n7-palmitoleate the serum indicates a risk of metabolic disease. Additionally, administering trans C16:1n7-palmitoleate to a subject (via pharmaceutical, nutraceutical, or other means), positively impacts glucose metabolism.
公开/授权文献
信息查询
